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Original ArticleCarbonyl reductase 1 amplifies glucocorticoid
action in adipose tissue and impairs glucose
tolerance in lean miceRachel M.B. Bell 1, Elisa Villalobos 1, Mark Nixon 1, Allende Miguelez-Crespo 1, Lee Murphy 2, Angie Fawkes 2,
Audrey Coutts 2, Matthew G.F. Sharp 3, Martha V. Koerner 3, Emma Allan 3, Onno C. Meijer 4, Renè Houtman 5,
Alex Odermatt 6, Katharina R. Beck 6, Scott G. Denham 7, Patricia Lee 7, Natalie Z.M. Homer 7,
Brian R. Walker 1,8, Ruth A. Morgan 1,9,*ABSTRACT
Objective: Carbonyl reductase 1 (Cbr1), a recently discovered contributor to tissue glucocorticoid metabolism converting corticosterone to 20b-
dihydrocorticosterone (20b-DHB), is upregulated in adipose tissue of obese humans and mice and may contribute to cardiometabolic compli-
cations of obesity. This study tested the hypothesis that Cbr1-mediated glucocorticoid metabolism influences glucocorticoid and mineralocorticoid
receptor activation in adipose tissue and impacts glucose homeostasis in lean and obese states.
Methods: The actions of 20b-DHB on corticosteroid receptors in adipose tissue were investigated first using a combination of in silico, in vitro,
and transcriptomic techniques and then in vivo administration in combination with receptor antagonists. Mice lacking one Cbr1 allele and mice
overexpressing Cbr1 in their adipose tissue underwent metabolic phenotyping before and after induction of obesity with high-fat feeding.
Results: 20b-DHB activated both the glucocorticoid and mineralocorticoid receptor in adipose tissue and systemic administration to wild-type
mice induced glucose intolerance, an effect that was ameliorated by both glucocorticoid and mineralocorticoid receptor antagonism. Cbr1
haploinsufficient lean male mice had lower fasting glucose and improved glucose tolerance compared with littermate controls, a difference that
was abolished by administration of 20b-DHB and absent in female mice with higher baseline adipose 20b-DHB concentrations than male mice.
Conversely, overexpression of Cbr1 in adipose tissue resulted in worsened glucose tolerance and higher fasting glucose in lean male and female
mice. However, neither Cbr1 haploinsfficiency nor adipose overexpression affected glucose dyshomeostasis induced by high-fat feeding.
Conclusions: Carbonyl reductase 1 is a novel regulator of glucocorticoid and mineralocorticoid receptor activation in adipose tissue that in-
fluences glucose homeostasis in lean mice.
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords Obesity; Glucocorticoid; Metabolism; Glucose; Corticosterone; Mineralocorticoid receptor; Glucocorticoid receptor1British Heart Foundation Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom 2Genetics Core,
Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom 3Transgenics Core, Bioresearch & Veterinary Services,
University of Edinburgh, Edinburgh, United Kingdom 4Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the
Netherlands 5Pamgene International, Den Bosch, the Netherlands 6Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of
Basel, Basel, Switzerland 7Mass Spectrometry Core Laboratory, Wellcome Trust Clinical Research Facility, The Queen’s Medical Research Institute, University of Edinburgh,
Edinburgh, United Kingdom 8Clinical and Translational Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom 9Royal (Dick) School of Veterinary
Studies, University of Edinburgh, Midlothian, United Kingdom
*Corresponding author. University of Edinburgh, Centre for Cardiovascular Science, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH14 6TJ,
United Kingdom.
E-mails: rachel.bell@ed.ac.uk (R.M.B. Bell), evillalo@exseed.ed.ac.uk (E. Villalobos), m.nixon@ed.ac.uk (M. Nixon), amiguele@exseed.ed.ac.uk (A. Miguelez-Crespo), lee.
murphy@ed.ac.uk (L. Murphy), a.fawkes@ed.ac.uk (A. Fawkes), aduncan5@exceed.ed.ac.uk (A. Coutts), matthew.sharp@ed.ac.uk (M.G.F. Sharp), m.koerner@ed.ac.uk
(M.V. Koerner), emma.murdoch@igmm.ed.ac.uk (E. Allan), o.c.meijer@lumc.nl (O.C. Meijer), rene@precisionmedicinelab.nl (R. Houtman), alex.odermatt@unibas.ch
(A. Odermatt), katharina.beck@wlab.gu.se (K.R. Beck), scott.denham@ed.ac.uk (S.G. Denham), t.lee1@exceed.ed.ac.uk (P. Lee), n.z.m.homer@ed.ac.uk
(N.Z.M. Homer), brian.walker@newcastle.ac.uk (B.R. Walker), ruth.morgan@ed.ac.uk (R.A. Morgan).
Abbreviations: Cbr1, carbonyl reductase 1; LC-MS/MS, liquid chromatography tandem mass spectrometry; 20b-DHB/F, 20b-dihydrocorticosterone/dihydrocortisol; GR,
glucocorticoid receptor; MR, mineralocorticoid receptor; SNPs, single nucleotide polymorphisms; PuroR, puromycin resistance; UTR, untranslated region; Tk, thymidine
kinase; NeoR, neomycin resistant: RMCE; recombination-mediated cassette exchange, NEFA; non-esterified fatty acids: GTT, glucose tolerance test; ITT, insulin tolerance
test; ELISA, enzyme-linked immunoassay; qPCR, quantitative polymerase chain reaction; 11b-HSD1/2, 11b-hydroxysteroid dehydrogenase type 1/2; DEGs, differentially
expressed genes
Received January 13, 2021  Revision received March 9, 2021  Accepted March 24, 2021  Available online 27 March 2021
https://doi.org/10.1016/j.molmet.2021.101225




Glucocorticoids act through widely expressed glucocorticoid receptors
(GR) and the more tissue-specific mineralocorticoid receptor (MR) to
modulate fuel metabolism, the immune system, and salt and water
balance. Adipose tissue expresses both GR and MR, and the balance of
activation between the two is an important determinant of adipose
tissue expansion, insulin sensitivity, and glucose homeostasis [1,2].
Excessive or chronic activation of GR and/or MR in adipose tissue
results in glucose intolerance and lipid accumulation and contributes to
metabolic syndrome [3e7]. Glucocorticoids are the main ligands of
GR, while MR binds both glucocorticoids and aldosterone. In classic
MR-responsive tissues such as the kidney, aldosterone binding is
favoured due to the presence of 11b-hydroxysteroid dehydrogenase
type 2 (11b-HSD2), which inactivates cortisol/corticosterone. In adi-
pose tissue, however, there is little 11b-HSD2, and glucocorticoids are
the primary ligands of MR [8]. Receptor activation by glucocorticoids in
adipose tissue is modulated by steroid-metabolising enzymes such as
11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) and 5a-re-
ductases, which catalyse the conversion of primary glucocorticoids
into more or less potent ligands of the receptors [9,10]. Dysregulation
of these glucocorticoid-metabolising enzymes in adipose tissue
directly contributes to insulin dysregulation [11,12] and can contribute
to the pathogenesis of obesity and cardiovascular disease [9,13,14].
We recently showed that the cytosolic enzyme carbonyl reductase 1
(Cbr1) is a novel regulator of tissue glucocorticoid metabolism that
converts cortisol/corticosterone into 20b-dihydrocortisol (20b-DHF) or
20b-corticosterone (20b-DHB), which are weak agonists of human
and murine GR [15]. Cbr1 and 20b-DHF/B are abundant in adipose
tissue and increased in obese adipose of humans and mice [15,16].
There is growing evidence that Cbr1 can affect metabolism and in
particular glucose homeostasis. Single nucleotide polymorphisms
(SNPs) in the human CBR1 gene that increase CBR1 expression are
causally associated with higher fasting blood glucose [15] and defi-
ciency of the key transcriptional regulator of Cbr1, Nrf2, improves
glucose tolerance in murine models [17]. Cbr1 was identified by RNA
sequencing as a key gene involved in the pathogenesis of a
streptozotocin-induced rat model of diabetes [18] and is significantly
upregulated in the rat heart in diabetes [19]. Reduced CBR1 may
contribute to the metabolic benefits of a Mediterranean diet since
polyphenol constituents are inhibitors of CBR1 [20,21]. Despite this
evidence, there have been no definitive intervention studies to test
CBR1’s role in metabolic health.
Having previously shown that 20b-DHF/B activates GR, we first tested
the hypothesis that 20b-DHB is a ligand of MR in adipose tissue and
that its administration impairs systemic glucose tolerance through
increased GR and MR activation. We then addressed the hypothesis
that global deficiency of Cbr1 reduces plasma and tissue 20b-DHB,
resulting in a reduction in GR and MR activation and improved glucose
tolerance with or without high-fat feeding. We also tested the hy-
pothesis that metabolic effects of Cbr1 are mediated by adipose tissue
using a model of adipose-specific overexpression.
2. METHODS
2.1. Animals
Animal experiments were approved by the University of Edinburgh
ethical committee and performed under the Provisions of the Animal
Scientific Procedures Act (1986) of the UK Home Office in accordance
with EU Directive 2010/63/EU.2 MOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier GMice heterozygous for Cbr1 deletion were generated; homozygosity of
this gene deletion is foetal lethal [22]. A targeting vector was designed
to introduce loxP sequences flanking Cbr1 exons 2 and 3 (including the
30 untranslated region) (Taconic Biosciences, Leverkusen, Germany).
The positive selection marker (puromycin resistance, PuroR) was
flanked by F3 sites and inserted downstream of the 3’ UTR. The tar-
geting vector was generated using BAC clones from the C57BL/6J
RPCI-23 BAC library and transfected into the Taconic Biosciences
C57BL/6NTac embryonic stem cell line. Homologous recombinant
clones were isolated using positive (PuroR) and negative (thymidine
kinase, Tk) selections. The constitutive knockout allele was obtained
by treating 1-cell embryos with soluble HTN-Cre enzyme (Excellgen,
Rockville, MD, USA) as previously described [23,24]. The mice were
genotyped by Transnetyx (Memphis, TN, USA) using real-time qPCR
(RT-qPCR).
To generate adipose-specific over-expressors of Cbr1, animals with
floxed Cbr1 (R26-Cbr1Fl) were first generated (Taconic Biosciences
GmBH). The following elements were inserted into the Rosa26 locus
using recombination-mediated cassette exchange (RMCE): a CAG
promoter cassette, a loxP-flanked transcription termination cassette
(STOP) containing a combination of polyadenylation signals, the Cbr1-
T2A-mKate2 open reading frame together with a Kozak sequence
(GCCACC), the human growth hormone (hGH) polyadenylation signal,
and an additional polyadenylation signal. The RMCE vector was
transfected into the Taconic Biosciences C57BL/6ES cell line equipped
with RMCE docking sites in the ROSA26 locus. Recombinant clones
were isolated using positive (Neomycin resistance- NeoR) selection.
The adipose-specific overexpressors (R26-Cbr1Adpq) were obtained by
crossing with Adiponectin-Cre mice [25]. The mice were genotyped by
Transnetyx using RT-qPCR.
Male and female mice were maintained in individual ventilated cages
at 21 C on a 12-h light/12-h dark cycle with free access to food and
water unless otherwise stated. The mice were given a high-fat diet
(D12331, Research Diets Inc., NJ, USA) for 8 weeks. Bodyweight and
food intake were measured weekly using a precision scale. Body
composition was determined using time-domain nuclear magnetic
resonance (Bruker, Billerica, MA, USA) before and after high-fat
feeding. Mice undergoing adrenalectomy were maintained on 0.9%
saline. Blood for glucocorticoid analysis was collected following
decapitation between 9 am and 10 am, and the animals were not
fasted.
2.2. Extraction and quantification of mRNA by RT-qPCR
Total RNA was extracted from adipose and liver using an RNeasy Mini
kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer’s
instructions. The tissue was mechanically disrupted in either QIAzol
(Qiagen) for adipose tissue or RLT buffer (Qiagen) for liver tissue. cDNA
was synthesised using a QuantiTect Reverse Transcription kit (Qiagen)
according to the manufacturer’s instructions. A quantitative real-time
polymerase chain reaction was performed using a LightCycler 480
(Roche Applied Science, Indianapolis, IN, USA). Primers were designed
using sequences from the National Centre of Biotechnological Infor-
mation and the Roche Universal Probe Library. The qPCR primer se-
quences are included in Supplementary Table 1. Samples were
analysed in triplicate and amplification curves plotted (y axis, fluo-
rescence; x axis, cycle number). Triplicates were deemed acceptable if
the standard deviation of the crossing point was <0.5 cycles. A
standard curve (y axis, crossing point; x axis, log concentration) for
each gene was generated by serial dilution of cDNA pooled from
different samples, fitted with a straight line, and deemed acceptable ifmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the reaction efficiency was between 1.7 and 2.1. The average of
housekeeping genes 18s, Tbp, and b-actin was used to normalise
gene expression.
2.3. Quantification of protein by western blotting
Protein lysates from subcutaneous adipose tissue and liver (30e
50 mg) were prepared in RIPA lysis buffer supplemented with protease
inhibitors (Thermo Fisher Scientific, Waltham, MA, USA). The protein
concentration was quantified using a bicinchoninic acid (BCA) assay
(Thermo Fisher Scientific). Extracted proteins (20 mg) were resolved by
SDS-PAGE using Criterion TGX Precast Protein Gels 4e20% (Bio-Rad)
under reducing and denaturing conditions. Proteins were transferred to
nitrocellulose membranes using the Trans-Blot Turbo Blotting System
(Bio-Rad). Membranes were blocked with skim milk at 5% in Tris-
buffered saline and then subjected to Western blotting using anti-
bodies specific for CBR1 (rabbit polyclonal IgG, cat. no. NBP1-86595,
Novus Biologicals) and b-actin (mouse monoclonal IgM, 7D2C10, cat.
no. 60008-1-Ig, Proteintech). The primary antibodies were used at
1:1000 and 1:5000 dilution in 3% BSA in Tris-buffered saline and
incubated overnight (4 C). Secondary antibodies IRDye 800CW or
IRDye 680CW (LI-COR) (anti-mouse and rabbit IgGs) were used at
1:10,000 dilution in 3% BSA in Tris-buffered saline and incubated for
1 h at room temperature. Protein detection was performed using an
Odyssey CLx Imaging system (LI-COR). Densitometric analyses were
performed using Image Studio Software (LI-COR).
2.4. CBR1 activity
CBR1 activity was determined in adipose and liver homogenised in
Krebs buffer as previously described [26]. Briefly, homogenates (1 mg/
mL of protein) were incubated with menadione (100 nM) and NADPH
(2 mM) and the absorbance measured at 340 nm at 25 C for 45 min
using a Spectra Max Plus microplate reader (Molecular Devices LLC).
Activity was defined as (DAbs340/min)/6.3 and expressed per mg of
protein.
2.5. Quantification of steroids in plasma and adipose by LC-MS/MS
Mouse plasma (100 mL) samples were prepared alongside calibration
standards (covering a range of 0.025e500 ng/mL) in a 96-well plate
enriched with internal standard (10 ng, d8-corticosterone, and d8-
aldosterone) and diluted with 0.1% formic acid in water (100 mL) on
a Biotage Extrahera liquid-handling robot. Diluted samples were
transferred to an SLEþ 200 plate and eluted into a collection plate with
dichloromethane/propan-2-ol (98:2; 4  450 mL). The eluate was
dried and reconstituted in water/methanol (70:30; 100 mL) before
injecting directly from the 96-well plate for LC-MS/MS analysis.
Adipose tissue samples (60e80 mg) were enriched with internal stan-
dard (0.5 ng; d8-corticosterone) homogenised (TissueLyser II, Qiagen) in
acetonitrile w/0.1% formic acid (500 mL). A calibration standard curve of
20b-DHB was prepared alongside the samples covering a range of
0.0025e10 ng. The samples were centrifuged and the supernatant
(500 mL) was transferred to an ISOLUTE PLDþ 96-well plate cartridge
(Biotage, Uppsala, Sweden), subjected to positive pressure, collected,
and dried under nitrogen gas (40 C). The samples were re-suspended in
H2O: MeOH (70:30; 100 mL), sealed before analysis.
Extracts were analysed by LC-MS/MS on a Shimadzu Nexera X2
connected to a QTrap 6500þ mass spectrometer (AB Sciex) adapted
from earlier methods [27]. Standards and samples were injected
(20 mL) onto a Kinetex C18 column (100  3.0 mm and 2.6 mm;
Phenomenex, UK) fitted with a 0.5 mm Ultra KrudKatcher (Phenom-
enex) using a mobile phase system of A 0.05 mM ammonium fluorideMOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comin water and methanol at 0.5 mL/min from 50 to 90% corticosterone
over 16 min. Mass transitions and retention times are detailed in the
supplementary materials. Peaks were integrated using Quantitate
software and the peak area ratio of 20b-DHB to d8-corticosterone
using least-squares regression with 1/x weighting was used to
calculate the amount of 20b-DHB in the samples, then normalised to
the tissue weight expressed as ng/g of tissue.
2.6. Glucose and insulin tolerance tests
For glucose tolerance tests, the mice were fasted for 6 h (0800e
1400 h) in clean cages and then given glucose (2 mg/g of bodyweight,
40% w/v in saline) via intraperitoneal injection. For insulin tolerance
tests, the mice were fasted for 4 h (1000e1400 h) and then admin-
istered 0.75 IU/kg of insulin (Eli Lilly, Indianapolis, IN, USA) via intra-
peritoneal injection. Blood was collected from the tail vein immediately
prior to and 15, 30, 60, 90, and 120 min after injection. Glucose was
measured immediately using a point-of-care glucometer (Accu-Chek
Aviva, Roche, Basel, Switzerland). Plasma insulin was measured using
an Ultra-Sensitive Mouse Insulin ELISA kit (Crystal Chem Inc., Elk Grove
Village, IL, USA). Plasma non-esterified fatty acids were measured by
ELISA (NEFA-HR, Wako Chemicals GmBH, Neuss, Germany) following
the manufacturer’s instructions.
2.7. 20b-DHF interaction with human mineralocorticoid receptor
Docking studies were performed using GOLD software version 5.2
(Cambridge Crystallographic Data Centre, Cambridge, UK) [28]. This
software allows the identification of precise docking poses for small
molecules in a protein’s binding pocket by applying a genetic algo-
rithm. The crystal structures with the Protein Data Bank (PDB) entry
2AA2 (DOI: 10.2210/pdb2AA2/pdb) was selected for MR. First the
respective co-crystallised ligand, aldosterone, was removed from the
binding pocket and re-docked into the binding site to examine whether
GOLD could restore the original binding position and therefore validate
the docking settings. The MR binding sites were defined by the ligand
surrounded by a 6 Å region lining the active site. Protein ligand in-
teractions determined by the docking software were further assessed
using LigandScout 3.12 (Inte:Ligand GmbH, Vienna, Austria, kindly
provided by Thierry Langer). Based on the chemical functionalities,
geometric distances, and angles between adjacent structures, this
software automatically evaluates the observed binding pattern be-
tween the protein and docked ligand [29]. A microarray assay for real-
time co-regulator-nuclear receptor interaction (MARCoNI) was used to
compare the quantitative and qualitative co-regulator recruitment
induced when 20b-DHF (1 mM) binds with human MR with that of
recruitment in response to aldosterone (1 mM) using a previously
described method [30].
2.8. In vitro mineralocorticoid receptor activation
Human embryonic kidney cell line HEK293 cells were obtained from
the European Collection of Cell Cultures (ECACC; distributor Sigmae
Aldrich, St. Louis, MO, USA). The cells were grown and maintained
in a humidified atmosphere (95% air, 5% CO2, and 37 C) in Dul-
becco’s modified Eagle’s medium (DMEM, Lonza Group Ltd., Basel,
Switzerland) supplemented with glucose (4.5 g/L), heat-inactivated
foetal bovine serum (HI-FBS) (10% v/v), penicillin (100 IU/mL), strep-
tomycin (100 mg/mL), and L-glutamine (2 mM). The cells were seeded
at 2  105 per 35-mm well. The cells were rinsed twice with PBS and
cultured in steroid-free medium for 24 h prior to experimentation. The
cells were transiently transfected with 1 mg of pMMTV LTR-luciferase,
1 mg of pKC275 (encoding b-galactosidase as an internal control), andan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
Original Article0.05 mg of murine MR. The cells were treated with vehicle (ethanol),
aldosterone (1014-105 M, SigmaeAldrich), or 20b-DHB (1012-
105 M, Steraloids, Newport, RI, USA) for 4 h and then lysed and
luciferase and b-galactosidase activities were measured as previously
described [31]. Galactosidase activity was assayed using a Tropix kit
(Applied Biosystems, Foster City, CA, USA). The mean ratio of lucif-
erase/b-galactosidase activities was calculated. Plasmids were a kind
gift from K.E. Chapman, Centre for Cardiovascular Science, University
of Edinburgh.
2.9. RNA sequencing analysis of adipose tissue
C57BL/6J male mice (8 weeks of age, n ¼ 6/group) underwent
adrenalectomy to remove endogenous steroids as previously described
[32]. Seven days post-surgery, subcutaneous mini-osmotic pumps
(Alzet, Cupertino, CA, USA) were implanted to deliver either vehicle
(DMSO/propylene glycol), the GR agonist dexamethasone, the MR
agonist aldosterone, or 20b-DHB (20 mg/day). After 7 days of treat-
ment, subcutaneous adipose tissue was harvested post mortem and
RNA extracted as previously described (Section 2.4). Total RNA sam-
ples were quantified using a Qubit 2.0 Fluorometer (Thermo Fisher
Scientific) and a Qubit RNA HS assay kit. RNA integrity was assessed
using an Agilent 2100 Bioanalyser System (Agilent Technologies Inc.)
and Agilent RNA 6000 Nano kit. Libraries were prepared from 500 ng
of each total RNA sample using a TruSeq Stranded mRNA Library kit
(Illumina Inc.). cDNA was synthesised and libraries quantified. These
and details on next-generation sequencing are given in the supple-
mentary materials.
2.10. Statistical analysis
Analyses were performed using Prism 8 software (GraphPad, San
Diego, CA, USA). All of the variables were assessed for normality using
the KolmogoroveSmirnov test. Comparisons between groups were
performed using Student’s t tests or the ManneWhitney test as
appropriate. Comparisons between groups at different time points and
between > 2 groups were assessed by one- or two-way ANOVA with
Bonferroni’s post hoc test. Data are presented as mean  SEM.
3. RESULTS
3.1. 20b-DHF/B was a full mineralocorticoid receptor agonist
in vitro
As there was no crystal structure of murine MR available, in silico
modelling of 20b-DHF, the human equivalent to 20b-DHB, was con-
ducted on the human MR. Docking calculations revealed similar in-
teractions with the residues of the MR ligand-binding pocket for 20b-
DHF and aldosterone. Both ligands formed hydrogen (H) bonds with
Gln776, Asn770, and Thr945. The 20b-hydroxyl group on 20b-DHF
formed an H bond with Met845, whereas the carbonyl group of
aldosterone at the same position showed an H bond with Cys942
(Figure 1A). Based on this, we predicted that upon binding to the re-
ceptor, 20b-DHF was likely to induce a transcriptional response. This
was tested in vitro using HEK293 cells transiently expressing murine
MR and a luciferase reporter under the control of a promoter with a
corticosteroid receptor response element. A doseeresponse curve
showed that 20b-DHB could fully activate murine MR (20b-DHB EC50
8.5  108 M vs aldosterone EC50 5.7  1011) (Figure 1B) and to a
lesser extent murine GR (partial agonism at EC50 2.5  106 [15]).
Thus, 20b-DHB was a more potent agonist of MR than GR in vitro.
On binding a ligand, the translocation to the nucleus and subsequent
transcriptional response to a steroid hormone-receptor complex is
largely determined by co-regulator recruitment [30]. We previously4 MOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier Gshowed that on binding to GR 20b-DHF recruits only 36% of co-
regulators recruited by cortisol [15]. On testing the effect of 20b-
DHF on MR, we found that 20b-DHF-MR binding recruited 93% of the
co-regulators recruited by the aldosterone-MR complex or cortisol-MR
complex (Figure 1CeD, Supplementary File 1) and recruitment by both
ligands was highly correlated (R2 ¼ 0.97, p < 0.0001) (Figure 1EeG),
that is to say that all of the co-regulators were recruited in the same
direction by both ligands and it was only the magnitude of fold change
that differed between the two. This was in line with the full agonism
observed in the transactivation assay.
3.2. 20b-DHB induced GR and MR-mediated transcriptional and
functional responses in vivo
These in vitro findings suggested that 20b-DHB would preferentially
activate MR over GR in vivo. To determine the relative activation of GR
and MR by 20b-DHB, we compared the transcriptional response of
subcutaneous adipose tissue to systemic infusion of either the GR
agonist dexamethasone, the MR agonist aldosterone, or 20b-DHB
(20 mg/day of each agonist) in wild-type mice (C57BL/6J) following
adrenalectomy to remove endogenous steroids. Candidate gene
expression analysis showed that dexamethasone and 20b-DHB
induced transcription of GR-responsive gene Pnpla2 and mixed GR/MR
target gene Tsc22d3 in subcutaneous adipose tissue (Figure 2A).
Unlike dexamethasone, 20b-DHB did not downregulate GR or Tnfa
(Figure 2A). The expression of MR-responsive gene Ptgds was
increased by aldosterone and 20b-DHB (Figure 2A). Given the rarity of
known MR-specific genes, we further explored the transcriptome
induced by each ligand using next-generation sequencing of the
subcutaneous adipose tissue.
20b-DHB differentially regulated 1039 genes (554 upregulated, 485
downregulated, Supplementary File 2), dexamethasone 8782 genes
(3939 upregulated, 4843 downregulated), and aldosterone 855 (303
upregulated, 552 downregulated) (Figure 2BeD) compared with
vehicle control (DMSO). 20b-DHB shared 54% of its differentially
expressed genes (DEGs) with dexamethasone but this accounted for
just 5% of the genes regulated by dexamethasone (561/8782), 15%
with aldosterone accounting for 18% of aldosterone-regulated genes
(155/855), and 8% with both; 24% were uniquely regulated by 20b-
DHB. We further analysed these genes for the presence of conserved
GR binding sites using oPOSSUM software [33]. Within the genes
uniquely differentially regulated by 20b-DHB, 10% (26/252) had
distinct GR transcription factor-binding sites (TFBS). This was similar
to, but slightly less than, the percentage of TFBS identified in the genes
uniquely regulated by dexamethasone (12%, 814/6414) and aldoste-
rone (15%, 50/315). Transcriptome interrogation of the shared DEGs
by KEGG and GO analysis showed that there were no significant
similarities in pathway enrichment between dexamethasone and 20b-
DHB or between aldosterone and 20b-DHB (data not shown). Analysis
of all genes differentially regulated by 20b-DHB demonstrated sig-
nificant downregulation of oxidative phosphorylation and mitochondrial
pathways (Figure 2EeF and Supplementary Tables 2e3) by both GO
and KEGG analysis, none of which were enriched by dexamethasone or
aldosterone.
Having demonstrated that 20b-DHB activates both GR and MR in
adipose tissue, male C57BL/6J mice (8 weeks of age) were admin-
istered 20b-DHB (20 mg/day) via subcutaneous mini-pumps for 7 days
with concurrent administration of vehicle, GR antagonist RU486
(mifepristone, 6 mg/kg/day), or MR antagonist spironolactone (20 mg/
kg/day) in drinking water. We found that administration of 20b-DHB
impaired glucose tolerance in the wild-type mice and that this effect
was ameliorated by antagonism of either GR or MR (Figure 2GeH).mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1: 20b-DHB is a full agonist of the mineralocorticoid receptor. (A) In silico comparison of 20b-DHF and aldosterone binding on the human MR. (B) A doseeresponse
curve of 20b-DHB and aldosterone in HEK293 cells transiently transfected with murine mineralocorticoid receptor. (C) Binding profile induced by aldosterone (red), cortisol (blue), or
20b-DHF (green) binding to mineralocorticoid receptor. Modulation index (MI) > 0 suggested ligand-favoured binding, while MI < 0 suggested ligand-disfavoured binding of a
peptide compared to DMSO; *p < 0.05 and **p < 0.01. (D) Heat map depiction of details of ligand-induced binding of co-regulator peptides using MARCoNI. The colour of the bar
represents the modulation index, that is, compound induced log-fold change of binding, red a positive fold change, and blue a negative fold change. (E-G) The correlation of co-
regulator recruitment between 20b-DHF and aldosterone. (E) 20b-DHF and cortisol (F) and cortisol and aldosterone (G).Fasting glucose was not different between the groups (Figure 2I). We
selected four genes uniquely downregulated by 20b-DHB in subcu-
taneous adipose tissue and overrepresented in KEGG and GO analysis
enrichment and determined their expression in these mice. We found
that both RU486 and spironolactone normalised the expression
(Supplementary Fig. S1).
3.3. Male but not female Cbr1 haploinsufficient mice had reduced
20b-DHB in adipose tissue
To determine the physiological effects of Cbr1/20b-DHB on glucose
homeostasis in the lean and obese state, mice heterozygous for Cbr1
deletion were generated (Cbr1þ/). Male and female control (Cbr1þ/þ)
and heterozygous (Cbr1þ/) littermates were born at the expected
Mendelian ratio but no homozygotes (Cbr1/) were born, confirming
that homozygosity of this gene deletion is foetal lethal. Cbr1 mRNA
expression in the subcutaneous adipose tissue of the Cbr1þ/ mice
was approximately 20e30% of that in their Cbr1þ/þ control litter-
mates (Figure 3A). CBR1 protein expression in the subcutaneous ad-
ipose of the male Cbr1þ/mice was approximately 50% of that in their
control littermates (Figure 3BeC). This model is globally deficient ofMOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comCbr1, which was confirmed by the gene expression and protein levels
in the liver and kidney (Supplementary Fig. S2). The female mice had a
similar reduction in mRNA, protein, and activity (Figure 3AeD).
Analysis of the glucocorticoid profile by LC-MS/MS demonstrated that
the male Cbr1þ/ mice had approximately 50% less 20b-DHB in their
plasma and an 80% less in their subcutaneous adipose tissue
compared to their Cbr1þ/þ control littermates (Figure 3EeF). The
female mice had a similar reduction in plasma 20b-DHB concentra-
tions but there was no difference in adipose tissue 20b-DHB content
(Figure 3EeF) and adipose corticosterone content was not different
between genotypes (Supplementary Fig. S3A). Plasma corticosterone
and aldosterone concentrations were not different between genotypes
(Figure 3GeH).
3.4. Cbr1 haploinsufficiency improved glucose tolerance in lean
male but not female mice but did not protect against the effects of
high-fat feeding
The male Cbr1þ/ mice had lower fasting glucose on a control chow
diet and a smaller area under the curve for plasma glucose following
intra-peritoneal glucose tolerance tests, indicating improved glucosean open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 5
Figure 2: 20b-DHB induced both GR- and MR-regulated genes in adipose tissue. (A) The mRNA expression of glucocorticoid receptor (GR), mineralocorticoid receptor (MR), GR-
responsive genes patatin-like phospholipase domain-containing 2 (Pnpla2) that encodes adipose triglyceride lipase (Atgl), Tsc22d3 that encodes glucocorticoid-induced leucine zipper
protein (GilZ), period 1 (Per1), tumour necrosis factor a (Tnfa), and MR-responsive gene prostaglandin D2 synthase (Ptdgs) (n ¼ 6/group). Data are mean  SEM. Statistical
significance was assessed by the ManneWhitney U test and two-way ANOVA as appropriate. *p < 0.05 relative to the wild-type control. (B) Venn diagram showing overlap of
significantly differentially expressed genes (DEGs) in response to aldosterone, dexamethasone, and 20b-DHB in subcutaneous adipose tissue. (C) Scatterplots of DEGs in response to
20b-DHB (red), aldosterone (blue), and both ligands (green). (D) Scatterplots of DEGs in response to 20b-DHB (red), dexamethasone (blue), and both ligands (green). (E) KEGG analysis
of the 20b-DHB mediated transcriptome showing the log p value for pathway enrichment. (F) Gene ontology analysis of 20b-DHB mediated transcriptome showing the log p-value for
pathway enrichment. (G) Glucose tolerance tests (GTT) in male mice administered 20b-DHB with concurrent vehicle, RU486, or spironolactone (n ¼ 4e5 mice/group) (H) Area under
the curve for GTT in the four groups. (I) Fasting plasma glucose concentrations. Data are mean  SEM. Statistical significance was assessed by ANOVA. *p < 0.05 and **p < 0.01.
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Figure 3: Lean Cbr1 heterozygous mice had reduced 20b-DHB in plasma and adipose tissue (A) Cbr1 mRNA expression in subcutaneous adipose tissue of lean male and
female mice (n ¼ 5e7 mice/group). (B) Representative Western blotting of CBR1 in the subcutaneous adipose tissue from the lean male Cbr1þ/þ and Cbr1þ/ mice (n ¼ 4 mice/
group).(C)Quantification of CBR1 in the subcutaneous adipose tissue from the lean male and female Cbr1þ/þ and Cbr1þ/ mice. (D) CBR1 activity in the subcutaneous adipose
tissue from the lean male and female Cbr1þ/þ and Cbr1þ/ mice (n ¼ 4 mice/group). (EeF) 20b-DHB quantified by LC-MS/MS in the plasma and subcutaneous adipose tissue
from the lean male and female Cbr1þ/þ and Cbr1þ/ mice (n ¼ 4e6 mice/group). (GeH) Plasma corticosterone and aldosterone quantified by LC-MS/MS in the plasma from the
lean male and female Cbr1þ/þ and Cbr1þ/ mice (n ¼ 5e6 mice/group). Data are expressed as mean  SEM. Statistical analysis was conducted with the ManneWhitney U test.
*p < 0.05, **p < 0.01, and ***p < 0.001.tolerance compared to the Cbr1þ/þ mice. Fasting plasma insulin, in-
sulin tolerance, and fasting plasma non-esterified fatty acid (NEFA) did
not differ between genotypes (Figure 4AeG). However, the female
Cbr1þ/ showed no difference in fasting glucose or glucose tolerance
compared to their littermate controls on a control chow diet
(Supplementary Fig. S4). When fed a control chow diet (4e8 weeks of
age) there were no differences between littermate controls and Cbr1þ/
 in bodyweight, lean or fat mass, and food or water intake between
the male (Figure 4HeK) or female mice (Supplementary Fig. S4).
We confirmed that these effects on metabolism were due to the role of
Cbr1 in glucocorticoid metabolism by administering 20b-DHB in
drinking water (100 mg/mL) for 7 days to the male mice. Administration
of 20b-DHB abolished the genotype difference in fasting glucose and
glucose tolerance observed on a control chow diet (Figure 5).
We previously showed that Cbr1 increased in adipose tissue in mice on
a high-fat diet. To determine the effect of Cbr1 deletion in obesity, the
male mice were fed a high-fat diet for 8 weeks. Transcript levels and
plasma 20b-DHB concentrations were still reduced in the Cbr1þ/
mice compared with their littermate Cbr1þ/þ controls but plasma
corticosterone was not different (Figure 6AeC). Weight gain, lean
mass, and fat mass did not differ between the genotypes following
high-fat feeding in the males (Figure 6D) or females (Supplementary
Fig. S4). High-fat feeding of the male mice abolished the difference
between genotypes in fasting glucose and glucose tolerance; fasting
insulin remained similar (Figure 6EeH). The female Cbr1þ/ mice
continued to demonstrate no significant differences in metabolic pa-
rameters on a high-fat diet compared with their littermate controls
(Supplementary Fig. S4).
3.5. Cbr1 overexpression in adipose tissue increased adipose 20b-
DHB concentrations
To test the hypothesis that adipose tissue Cbr1 specifically mediates
the effects on systemic glucose tolerance, we generated adipose-MOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comspecific over-expressors of Cbr1 (R26-Cbr1Adpq) by crossing condi-
tional knock-in mice with adiponectin-Cre mice. The mKate expres-
sion, used as a surrogate for recombination, was only detected in the
adipose tissue of the R26-Cbr1Adpq mice and not in R26-Cbr1Fl (data
not shown). The mRNA expression of Cbr1 was approximately 60%
higher in the R26-Cbr1Adpq male mice than in their floxed littermate
controls but only 20% higher in the female R26-Cbr1Adpq mice
(Figure 7A). Protein and activity were approximately doubled in the
male and female R26-Cbr1Adpq mice compared with floxed controls
(Figure 7BeC). The R26-Cbr1Adpq mice had approximately twice as
much 20b-DHB in their subcutaneous adipose tissue as the floxed
littermate controls (1.6 vs 4.2 ng/g adipose, p ¼ 0.0003) (Figure 7De
F). Adipose corticosterone content was not different between geno-
types (Supplementary Fig. S3B). There were no differences in the
plasma 20b-DHB or corticosterone concentrations (Figure 7G). There
was no increase in mRNA expression in the liver of the R26-Cbr1Adpq
mice compared with controls (Supplementary Fig. S5).
3.6. Adipose-specific overexpression of Cbr1 worsened metabolic
status in lean mice but did not exacerbate the effects of high-fat
feeding
When fed a control chow diet, there were no differences in bodyweight
or lean or fat mass between the male or female R26-Cbr1Adpq and their
floxed littermate controls (Supplementary Fig. S6). The male R26-
Cbr1Adpq mice had higher fasting glucose on a chow diet (9.5  0.3
vs 8.4  0.3, p ¼ 0.04) and a larger area under the curve of plasma
glucose following intra-peritoneal glucose tolerance tests (1819  66
vs 1392  14, p ¼ 0.03) (Figure 8AeC). The female R26-Cbr1Adpq
mice had a larger area under the curve of plasma glucose following
intra-peritoneal glucose tolerance tests but fasting glucose was not
different between the genotypes (Figure 8DeF). Fasting insulin and
fasting NEFA did not differ between the genotypes in either sex on
either diet (Supplementary Fig. S6). High-fat feeding of the male andan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 7
Figure 4: Deletion of Cbr1 improved glucose tolerance in the lean male mice. (A) Glucose tolerance tests (GTT) in the Cbr1þ/þ and Cbr1þ/ mice (n ¼ 14 mice/group). (B) Area
under the curve for GTT. (CeD) Fasting plasma glucose and insulin concentrations in the Cbr1þ/þ and Cbr1þ/ mice (n ¼ 6e10 mice/group). (E) Insulin tolerance test (ITT) in the
Cbr1þ/þ and Cbr1þ/ mice (n¼ 6 mice/group). (F) ITT area under the curve. (G) Fasting plasma concentrations of non-esterified fatty acid (NEFA). (HeI) Lean mass and fat mass as a
percentage of bodyweight in the Cbr1þ/þ and Cbr1þ/ mice (n¼ 4e6 mice/group). (JeK) Average food and water intake normalised to bodyweight in the Cbr1þ/þ and Cbr1þ/ mice
(n ¼ 3e5 mice/group). Data are expressed as mean  SEM. Statistical analysis was conducted with the ManneWhitney U test. *p < 0.05, **p < 0.01, and ***p < 0.001.
Original Articlefemale mice abolished the difference between genotypes in fasting
glucose and glucose tolerance (Figure 8AeF). The mRNA expression of
GR- and MR-responsive genes in the subcutaneous adipose tissue
showed a similar pattern to that seen when 20b-DHB was adminis-
tered to adrenalectomised mice (Figure 8G and Figure 2A). The GR and
MR levels were unaltered. GR-induced genes Pnpla2, Tsc22d3, and
Per1 increased in R26-Cbr1Adpq. Tnfa, which is downregulated by GR
activation, was unaltered by the genotype (Figure 8G). The expression
of MR-responsive gene Ptgds also increased in R26-Cbr1Adpq
compared with floxed controls (Figure 8G). These results were
consistent with mixed GR and MR activation in adipose tissue.
4. DISCUSSION
In this study, we showed that carbonyl reductase 1 is a novel regulator
of glucocorticoid and mineralocorticoid receptor activation in adipose8 MOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier Gtissue with a role in regulating glucose homeostasis. We showed that
20b-DHB activates both GR and MR in adipose tissue but has a
transcriptional profile that is distinct from either dexamethasone or
aldosterone and characterised by the downregulation of oxidative
phosphorylation and mitochondrial pathways. Furthermore, we
demonstrated that systemic administration of 20b-DHB worsens
glucose tolerance and this effect is ameliorated by antagonism of both
GR and MR. We found that Cbr1 haploinsufficiency improves glucose
tolerance and lowers fasting glucose, but only when accompanied by a
concurrent reduction in adipose and plasma 20b-DHB concentrations
as seen in the male but not female mice. Restoring 20b-DHB levels
without altering corticosterone levels “rescued” the phenotype of the
Cbr1þ/ mice. The importance of adipose CBR1/20b-DHB in medi-
ating the metabolic effects of Cbr1 was further supported by the
phenotype observed in mice with adipose-specific overexpression of
Cbr1, with both males and females demonstrating increased levels ofmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 5: Supplementation with 20b-DHB abolished genotype differences in glucose tolerance. (A) Plasma 20b-DHB concentrations before and after supplementation in
drinking water for 7 days in the male Cbr1þ/þ and Cbr1þ/ mice (n ¼ 6e7 mice/group). (B) Glucose tolerance tests (GTT) prior to and following 7 days of supplementation with
20b-DHB (n ¼ 8e9 mice/group). (C) Area under the curve for GTT. (D) Fasting plasma glucose prior to and following 7 days of supplementation with 20b-DHB (n ¼ 5e8 mice/
group). Data are expressed as mean  SEM. Statistical analysis was conducted with the ManneWhitney U test, a two-way ANOVA, and Bonferroni’s post hoc correction.
*p < 0.05, **p < 0.01, and ***p < 0.001.20b-DHB in adipose but not plasma and both sexes having worsened
glucose tolerance. Unlike other models of altered glucocorticoid action
in adipose tissue, the influence of adipose CBR1/20b-DHB on glucose
tolerance was not associated with altered fat mass or bodyweight and
was attenuated by high-fat feeding, suggesting that 20b-DHB mod-
ulates a different balance of effects compared with “conventional” GR
ligands.
Sex-specific effects of Cbr1 manipulation were previously reported in
studies investigating the role of Cbr1 in doxorubicin metabolism.
Freeland et al. observed that female Cbr1þ/ mice were not protected
against the cardiotoxic effects of doxorubicin to the same extent as male
Cbr1þ/ mice and suggested that this was because tissue Cbr1 levelsFigure 6: Cbr1 deletion did not protect against the metabolic effects of high-fat feed
(as shown in Figure 3) and high-fat diet (HFD) (n ¼ 6e7 mice/group). (B) Plasma 20b-DHB
and high-fat diet (n ¼ 6e10 mice/group). (C) Plasma corticosterone concentrations in m
(n ¼ 9e10 mice/group). (D) Weight gain in the male Cbr1þ/þ and Cbr1þ/ mice on the ch
Glucose tolerance tests (GTT) in the male Cbr1þ/þ and Cbr1þ/ mice following 8 weeks of
glucose concentrations in the male Cbr1þ/þ and Cbr1þ/ mice following 8 weeks of high-
and Cbr1þ/ mice following 8 weeks of high-fat feeding (n ¼ 7 mice/group). Data are exp
Bonferroni’s post hoc correction. *p < 0.05, **p < 0.01, and ***p < 0.001.
MOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier GmbH. This is
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report enzyme activity [34]. Differences in CBR1 expression in humans
are thought to account for the increased susceptibility of women [35]
and ethnic minorities to doxorubicin toxicity [36]. In our study, Cbr1
mRNA expression and activity were higher in the adipose tissue in the
control females than males but haploinsufficiency resulted in similarly
low levels of mRNA expression and activity in the males and females
and was therefore unlikely to account for the differences between the
sexes. Explanations for the disparity between adipose Cbr1 and 20b-
DHB levels in the females include the following possibilities: CBR1 is not
the only enzyme responsible for 20b-DHB production in females,
removal of 20b-DHB from the adipose differs between sexes, or ining. (A) mRNA expression of Cbr1 in the male Cbr1þ/þ and Cbr1þ/ mice on the chow
concentrations in the male Cbr1þ/þ and Cbr1þ/ mice on chow (as shown in Figure 3)
ale Cbr1þ/þ and Cbr1þ/ mice on the chow (as shown in Figure 3) and high-fat diet
ow diet up to 10 weeks of age and then on the high-fat diet (n ¼ 7e10 mice/group). (E)
high-fat feeding (n ¼ 9e11 mice/group). (F) Area under the curve for GTT. (G) Fasting
fat feeding (n ¼ 10 mice/group). (H) Fasting insulin concentrations in the male Cbr1þ/þ
ressed as mean  SEM. Statistical analysis was conducted with two-way ANOVA and
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Figure 7: Mice overexpressing Cbr1 in adipose tissue had increased 20b-DHB in adipose tissue but not plasma. (A) Cbr1 mRNA expression in the subcutaneous adipose
tissue of the male and female mice (n ¼ 4e6 mice/group). (B) Representative Western blotting of CBR1 in the subcutaneous adipose tissue from the male R26-Cbr1Fl and R26-
Cbr1Adpq mice (n ¼ 4 mice/group). (C) Quantification of CBR1 in the subcutaneous adipose tissue from the male and female R26-Cbr1Fl and R26-Cbr1Adpq mice. (D) CBR1 activity in
the subcutaneous adipose tissue from the male and female R26-Cbr1Fl and R26-Cbr1Adpq mice (n ¼ 4 mice/group). (EeF) 20b-DHB quantified by LC-MS/MS in the plasma and
subcutaneous adipose tissue from the male and female R26-Cbr1Fl and R26-Cbr1Adpq mice (n ¼ 4e6 mice/group). (G) Plasma corticosterone quantified by LC-MS/MS in the
plasma from the male and female R26-Cbr1Fl and R26-Cbr1Adpq mice (n ¼ 4e5 mice/group). Data are expressed as mean  SEM. Statistical analysis was conducted with the
ManneWhitney U test and two-way ANOVA. *p < 0.05 and **p < 0.01.
Original Articlefemale adipose, CBR1 always favours corticosterone as a substrate
whereas in males, competitive or alternative substrates are available
that are preferentially metabolised when CBR1 levels are reduced. The
female Cbr1þ/ mice had a reduction in plasma concentrations of 20b-
DHB but did not have a reduction in adipose tissue concentrations,
suggesting that other tissues, such as the gut, may contribute more
20b-DHB to the circulating pool than adipose, supported by the finding
that plasma levels were not increased in the adipose-specific Cbr1
overexpressing mice. The fact that adipose 20b-DHB and glucose
tolerance was unaltered in the female Cbr1þ/ supported the hy-
pothesis that adipose 20b-DHB was the driver of the phenotype
observed in the males. This was further supported by the presence of
increased 20b-DHB levels in the adipose tissue of the female R26-
Cbr1Adpq mice and worsened glucose tolerance.
It appears from this study that CBR1/20b-DHB modulates systemic
glucose tolerance via a paracrine effect in adipose tissue and not by
endocrine signalling from adipose to other tissues. A reduction in
plasma 20b-DHB when not accompanied by a reduction in adipose
20b-DHB as in the female Cbr1þ/ mice was not associated with an
improvement in glucose tolerance. Conversely, in the R26-Cbr1Adpq
mice, worsened glucose tolerance was present without a change in
plasma 20b-DHB. Administering 20b-DHB systemically resulted in
plasma concentrations of more than 10 times the physiological con-
centrations but the change in glucose tolerance had a similar
magnitude to that seen with only a doubling of adipose 20b-DHB
concentrations in the R26-Cbr1Adpq mice. It is well documented that
manipulating glucocorticoid action in adipose tissue can have systemic
effects on metabolic parameters, for example, mice over-expressing
11b-HSD1 in adipose tissue have glucose intolerance but unlike
Cbr1 over-expressors, they also demonstrate increased fat mass and10 MOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier Gfree fatty acids [3]. The difference in phenotype between these two
models, both of which increase corticosteroid receptor activation, is
most likely due to ligand-specific transcriptional responses when re-
ceptors are activated by 20b-DHB. It may also be due to a particular
balance of GR and MR activation induced by 20b-DHB, in which our
data suggest relatively potent MR activation; the interaction of GR and
MR in determining metabolic parameters is complex and still incom-
pletely understood with conflicting data from genetic models manip-
ulating each receptor [1,2,7,37,38].
Glucocorticoids acting on GR and MR have diverse effects on adipose
tissue biology, including reducing glucose uptake, increasing lipolysis,
and regulating inflammation and adipokine release. Our study showed
that 20b-DHB is a ligand of both receptors and although our in vitro
data suggested that there would be a preferential activation of MR, the
in vivo investigations made it apparent that the most pronounced
functional effects on glucose tolerance were ameliorated by antago-
nism of both GR and MR. Impairment of glucose tolerance by
decreasing glucose uptake and metabolism is induced by excess
dexamethasone activating GR, excess corticosterone activating both
GR and MR, and overexpression of MR in adipose tissue [4e7]. It has
also been shown that combined antagonism of GR and MR improves
glucose tolerance [39,40]; the effect of 20b-DHB demonstrated herein
is therefore consistent with that of a mixed GR/MR agonist. Interest-
ingly, the effects of dexamethasone on glucose uptake are more
marked under basal conditions compared with insulin-stimulated
conditions, which may also be the case for 20b-DHB given that
overexpression of Cbr1 did not worsen glucose tolerance during high-
fat feeding [41]. We found no evidence of an effect of CBR1/20b-DHB
on lipolysis or inflammatory markers within the adipose tissue. Tnfa
expression was not downregulated by 20b-DHB and there were nombH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 8: Adipose-specific overexpression of Cbr1 worsened metabolic status on a chow diet but did not exacerbate the effects of high-fat feeding. (A) Glucose
tolerance tests (GTT) in the male R26-Cbr1Fl and R26-Cbr1Adpq mice on a chow diet and after high-fat feeding (n ¼ 5e7 mice/group). (B) Area under the curve for GTT in the male
mice. (C) Fasting plasma glucose concentrations in the male R26-Cbr1Fl and R26-Cbr1Adpq mice (n ¼ 6e10 mice/group). (D) Glucose tolerance tests (GTTs) in the female R26-
Cbr1Fl and R26-Cbr1Adpq mice on a chow diet and after high-fat feeding (n ¼ 6e9 mice/group). (E) Area under the curve for GTTs in the female mice. (F) Fasting plasma glucose
concentrations in the female R26-Cbr1Fl and R26-Cbr1Adpq mice (n ¼ 6e8 mice/group). (G) The mRNA expression of glucocorticoid receptor (GR), mineralocorticoid receptor (MR),
GR-responsive gene patatin-like phospholipase domain containing 2 (Pnpla2) that encodes adipose triglyceride lipase (Atgl), Tsc22d3 that encodes glucocorticoid-induced leucine
zipper protein (Gilz), period 1 (Per1), tumour necrosis factor a (Tnfa), and MR-responsive gene prostaglandin D2 synthase (Ptdgs) in the subcutaneous adipose tissue of the male
R26-Cbr1Fl and R26-Cbr1Adpq mice on a chow diet (n ¼ 6e7/group). Data are mean  SEM. Statistical significance was assessed by the ManneWhitney U test and ANOVA.
*p < 0.05 and **p < 0.01.inflammatory pathways significantly downregulated by 20b-DHB. That
20b-DHB has divergent effects compared with other glucocorticoids
and aldosterone is unsurprising given that these receptors induce
ligand-specific effects [42]. The distinct nature of the transcriptional
response is in part due to co-regulator recruitment [43] and although
20b-DHF on binding to MR recruited almost 93% of the co-regulators
recruited by binding aldosterone or cortisol it is clear that even very
small differences in co-regulator recruitment can result in a markedMOLECULAR METABOLISM 48 (2021) 101225  2021 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comdifference in transcriptional response [44]. Moreover, the assay that
we used only probes co-regulator interactions with the receptor ligand-
binding domain and not the N-terminal part of the receptor. Our
transcriptomic analysis demonstrated that while a significant number
of 20b-DHB-associated DEGs were shared with dexamethasone
(54%), only 15% were shared with aldosterone and there was no
commonality in pathway enrichment between the ligands. We would
therefore suggest that 20b-DHB induces a ligand-specific responsean open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 11
Original Articlewhen binding adipose GR and MR due to the large (GR) or subtle (MR)
differences in co-regulator recruitment [45] or potentially the formation
of heterodimers of receptors, which was not investigated in this
study [46].
That Cbr1 deletion did not protect from the effects of a high-fat diet is
somewhat surprising, particularly given the increase in Cbr1 observed
in obese adipose in humans and mice [15]. One explanation for this is
the role of CBR1 in the context of oxidative stress [47]. CBR1 is
upregulated in oxidative stress; it inactivates highly reactive lipid al-
dehydes [47], ameliorates lipid peroxidation [48], and when overex-
pressed in hepatic cell lines confers protection against reactive oxygen
species-induced cell damage [49]. CBR1 in pancreatic b cells appears
to attenuate apoptosis and increase cell survival and insulin secretion
in vitro under glucotoxic conditions [50]. Therefore, under normal diet
conditions, a lack of CBR1 may be beneficial due to a reduction in GR/
MR activation by 20b-DHB, but when oxidative stress increases in
obesity, its absence is detrimental, cancelling out any protective ef-
fects. Equally, while overexpression in the adipose of lean mice may be
detrimental due to chronic activation of GR/MR, it is likely to be
beneficial when adipose expands and reactive oxygen species in-
crease. Alternative endogenous substrates of CBR1 include prosta-
glandins [47,51], and the foetal lethality of Cbr1/ mice has been
attributed to altered prostaglandin degradation in the amnion or uterus
[22]. High-fat feeding is associated with inflammation and increased
prostaglandins in adipose tissue [52]. Reduction in CBR1 may result in
excess prostaglandin content within the adipose tissue, which miti-
gates the protective effect of reduced GR/MR activation.
In conclusion, we have for the first time described CBR1/20b-DHB as a
novel mediator of glucocorticoid action in adipose tissue with a sig-
nificant impact on systemic glucose homeostasis in the lean state.
There is a very wide variation in CBR1 expression in human pop-
ulations [53e55]; common environmental factors such as cigarette
smoke upregulate the enzyme [56] and CBR1 inhibitors are present in
many foods and supplements [57]. Our data suggest that these vari-
ations may have important consequences for an individual’s gluco-
corticoid metabolism and metabolic health and that these
consequences should be considered when manipulating CBR1 for
other reasons such as cancer treatment.
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